Protein Design and Structure

Erscheinungsjahr 2022
ISBN: 978-0-323-99229-9
Verlag: William Andrew Publishing

Buch, Englisch, 432 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 840 g

Protein Design and Structure, Volume 130 in the Advances in Protein Chemistry and Structural Biology series, highlights new advances in the field, with this new volume presenting interesting chapters. Each chapter is written by an international board of authors.

Zielgruppe

Researchers and students

Autoren/Hrsg.

Donev, Rossen

Fachgebiete

• Naturwissenschaften Biowissenschaften Biowissenschaften DNA und Transgene Organismen
• Naturwissenschaften Biowissenschaften Molekularbiologie
• Naturwissenschaften Biowissenschaften Biochemie (nichtmedizinisch)
• Naturwissenschaften Biowissenschaften Zellbiologie

Inhaltsverzeichnis

1. Algorithms for protein design
Sekhar Talluri
2. Computational prediction of protein functional sites-Applications in biotechnology and biomedicine
Florencio Pazos
3. Structure and chemistry of enzymatic active sites that play a role in the switch and conformation mechanism
Chandrabose Selvaraj, Ondipilliraja Rudhra, Abdulaziz S. Alothaim, Mustfa Alkhanani, and Sanjeev Kumar Singh
4. Accelerating therapeutic protein design
Mohammad ElGamacy
5. Aromatic interactions directing peptide nano-assembly
Sajitha Sasidharan and Vibin Ramakrishnan
6. Understanding binding affinity and specificity of modular protein domains: A focus in ligand design for the polyproline-binding families
Jose C. Martinez, Francisco Castillo, Javier Ruiz-Sanz, Javier Murciano-Calles, Ana Camara-Artigas, and Irene Luque
7. The structural basis of histone modifying enzyme specificity and promiscuity: Implications for metabolic regulation and drug design
Tim J. Kamerzell, Brittney Mikell, Lei Chen, Harold Elias, Buddhadeb Dawn, Calum MacRae, and C. Russell Middaugh
8. Designing synthetic transcription factors: A structural perspective
Aparna Boral, Madhurima Khamaru, and Devrani Mitra
9. Recent advances in structural studies of 14-3-3 protein complexes
Nikolai N. Sluchanko
10. Immunosafe(r)-by-design nanoparticles: Molecular targets and cell signaling pathways in a next-generation model proxy for humans
Annalisa Pinsino and Maria Di Bernardo
11. Mutations in G6PC2 gene with increased risk for development of type 2 diabetes: Understanding via computational approach
S. Udhaya Kumar, Balu Kamaraj, Rinku Polachirakkal Varghese, V. Anu Preethi, R. Bithia, and C. George Priya Doss
12. Computational structural assessment of BReast CAncer type 1 susceptibility protein (BRCA1) and BRCA1-Associated Ring Domain protein 1 (BARD1) mutations on the protein-protein interface
D. Thirumal Kumar, S. Udhaya Kumar, Nikita Jain, Baviri Sowmya, Kamakshi Balsekar, R. Siva, Balu Kamaraj, Mariem Sidenna, C. George Priya Doss, and Hatem Zayed
13. Evolutionary aspect of Miltefosine transporter proteins in Leishmania major
Ritika Kabra and Shailza Singh

Über Autor(innen)

Donev, Rossen
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.